科学家们预测,可能会出现另一场疫情。他们已经确定了可能导致这种病毒的病毒——尽管卫生与公众服务部告诉我们,很少有针对这些病毒的抗病毒药物获得批准或正在卫生与公众事务部资助的临床试验中
根据约翰斯·霍普金斯彭博公共卫生学院研究人员的一项研究,截至3月底,大多数正在进行的COVID-19潜在治疗方法的注册临床试验的设计方式将大大限制其在理解潜在治疗方法方面的价值。
When the Max Planck Society established the Lead Discovery Center (LDC) for the development of new medicinal compounds in 2008, only a few people believed it would be successful. Ten years later, researchers at the LDC are now working on around 20 projects involving searches for new substances that can be used for medicinal purposes. One of the compounds developed at the LDC is already being tested in clinical studies on humans, while another is soon to reach this phase. Along with academic organizations and public entities such as the Max Planck Society the Helmholtz Association and the state of North Rhine-Westphalia, a number of pharmaceutical and biotech companies such as Bayer, Boehringer Ingelheim, Gruenenthal and Merck are also involved with the development of medicinal compounds at the LDC in the capacity of licensees or cooperative partners.